Fig. 2

(P)RR level in CRC is related to clinical characteristics and the activation of Wnt/β-catenin signalling. a Comparison of percentages of patients showing strong, middle or weak (P)RR expression in different stages (n = 20 in each stage). b Comparison of percentages of patients showing strong, middle or weak (P)RR expression in groups with and without recurrence and/or metastasis to other organ(s) (n = 23 without recurrence and metastasis; n = 37 with recurrence and/or metastasis). c Relevancy between (P)RR expression level and recurrence-free survival time of 20 patients in Stage II (n = 10) and III (n = 10) who had recurrence after radical operation (n = 16 with weak or middle (P)RR expression; n = 4 with strong (P)RR expression). d Comparison of percentages of patients showing strong, middle or weak (P)RR expression in groups with and without a 5-year survival (5-year follow-up after diagnosis of CRC was accomplished on 47 patients; 25 patients had survived over 5 years; 22 patients died within 5 years). e Representative IHC images of active β-catenin and c-Myc staining in CRC tissues with different (P)RR levels. Black arrow: staining of active β-catenin translocated into nuclei. *P < 0.05, ***P < 0.001